Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGF enemas vs mesalazine enemas in mild-to-moderate left-sided ulcerative colitis or proctitis
2006-002036-25Phase 3Terminated
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of epidermal growth factor in autoimmune colitis and ulcerative proctitis (2 arms), sponsored by University Hospitals of Leicester NHS Trust. Primary endpoint: Ulcerative colitis clinical remission at week 2. Started Feb 2012; status: terminated.
02
Drugs
epidermal growth factor
03
Conditions
autoimmune colitisulcerative proctitis
Beyond the preview
Go deeper on 2006-002036-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002036-25.